Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prostate cancer vaccine - NewLink Genetics

Drug Profile

Prostate cancer vaccine - NewLink Genetics

Alternative Names: HyperAcute Prostate

Latest Information Update: 19 Dec 2012

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NewLink Genetics Corporation
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Suspended Prostate cancer

Most Recent Events

  • 13 Dec 2012 Final efficacy, adverse events, pharmacodynamics and immunogenicity data from a phase I/II trial in Prostate cancer released by NewLink Genetics Corporation
  • 22 May 2008 Immunogenicity data from a phase I/II trial in hormone-refractory Prostate cancer presented at the 103rd Annual Meeting of the American Urological Association (AUA-2008)
  • 31 Mar 2005 Phase-I/II clinical trials in Prostate cancer in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top